Pervasis Therapeutics, Inc.

Pervasis Therapeutics Expands Team to Bring to Market Medical Therapies for Treating Cardiovascular Diseases

Pervasis Therapeutics Expands Team to Bring to Market Medical Therapies for Treating Cardiovascular Diseases

September 30, 2005

Cell Therapy Company Adds Industry Heavyweights to Leadership Team

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 30, 2005 - Pervasis Therapeutics, Inc., a biotechnology company founded to develop the next generation of medical therapies that integrate biomaterials with cells and drugs, today announced several recent additions to its quickly growing team, including a president, senior advisor and two independent directors.

Zalicus

CombinatoRx and Angiotech Sign Agreement to Apply CombinatoRx's Pipeline and Technology to the Field of Intervational Medicines

CombinatoRx and Angiotech Sign Agreement to Apply CombinatoRx's Pipeline and Technology to the Field of Intervational Medicines

October 3, 2005

CombinatoRx to receive $42 million on closing: $27 Million Upfront plus $15 Million Equity Investment To Discover and Develop Drug-Device Combinations and Local Interventional Medicines

e-Dialog, Inc.

e-Dialog Ranks Highest Overall Among Service-Oriented E-mail Marketing Providers in Independent Survey

e-Dialog Ranks Highest Overall Among Service-Oriented E-mail Marketing Providers in Independent Survey

October 18, 2005

Prominent Analyst Cites Company's Business Value, Account Servicing, Strategic and Creative Input, Campaign Management and Analysis Applications as Keys to Success

BG Medicine, Inc.

BG Medicine and FDA to Conduct Joint Biomarker Discovery Study to Improve Prediction of Human Liver Toxicity in Drug Development Process

BG Medicine and FDA to Conduct Joint Biomarker Discovery Study to Improve Prediction of Human Liver Toxicity in Drug Development Process

October 25, 2005

Study to Provide Solutions to Primary Obstacles in the Development of New Pharmaceuticals

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Predicition

AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Predicition

November 2, 2005

Agreement Marks First Application of Novel Platform for Predicting Clinical Response Based on Genetic Profiles

Zalicus

CombinatoRx, Incorporated Announces Pricing of Its Initial Public Offering

CombinatoRx, Incorporated Announces Pricing of Its Initial Public Offering

November 9, 2005

BOSTON, Nov 09, 2005 (BUSINESS WIRE) -- CombinatoRx, Incorporated (Nasdaq: CRXX) today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by CombinatoRx. In addition, CombinatoRx has granted the underwriters an option to purchase up to an additional 900,000 shares to cover over-allotments, if any.

Affinnova, Inc.

Affinnova Names Waleed Al-Atraqchi as CEO and President

Affinnova Names Waleed Al-Atraqchi as CEO and President

November 14, 2005

Seasoned consumer packaged goods and marketing services executive to lead company

Black Duck Software, Inc.

Black Duck Expands Advisory Board With Prominent Industry Executives and Academics

Black Duck Expands Advisory Board With Prominent Industry Executives and Academics

December 5, 2005

WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 5, 2005--Black Duck Software, the leading provider of software compliance management solutions, today announced that it has expanded its corporate advisory board with seven prominent industry executives and academics. Alex Aiken, Dave Bernstein, Dan Bricklin, Dave Flaschen, Ed Roberts, Jothy Rosenberg and Arthur Tyde have joined Larry Rosen, the noted open source and intellectual property attorney, as industry advisors.

EXACT Sciences

EXACT Sciences and Apogent Discoveries Announce Patent Licensing Agreement

EXACT Sciences and Apogent Discoveries Announce Patent Licensing Agreement

December 13, 2002

MAYNARD - December 13, 2002 -- EXACT Sciences Corporation and Apogent Discoveries announced today that they have executed a licensing agreement regarding certain patents owned by Apogent relating to its Acrydite™ technologies. The license provides EXACT Sciences, and its partners, with the ability to manufacture and use Acrydite in EXACT Sciences' PreGen-Plus™ assay. PreGen-Plus™ is EXACT Sciences' proprietary fecal DNA assay to detect colorectal cancer in the average-risk population. Terms of the agreement were not disclosed.

CGI Pharmaceuticals, Inc.

Cellular Genomics Establishes Research Collaboration With Lilly

Cellular Genomics Establishes Research Collaboration With Lilly

December 17, 2003

BRANFORD, Conn., Dec. 17 /PRNewswire/ -- Cellular Genomics Inc. (CGI), a chemical genetics based biopharmaceutical company, today announced that it has entered into a research collaboration with Eli Lilly and Company, under which CGI will apply its chemical genetics Analog Sensitive Kinase Allele (ASKA) technology to the study of kinase drug targets selected by Lilly.